A new way to detect metastatic prostate tumors using molecular imaging has shown promise in an early phase clinical trial. The noninvasive technique takes advantage of a prostate cancer-specific marker on the surface of prostate cancer cells. Continue reading…
- Tc-99m MIP-1404
A novel imaging technique is being studied as a tool to specifically detect prostate cancer cells located within the prostate gland, along with prostate cancer cells that have metastasized to other sites of the body. The technique uses a radiolabeled amino acid compound called Tc-99m MIP-1404, which is injected into the blood stream and then attaches to the PSMA enzyme located on prostate cancer cells. The radiolabeled prostate cancer cells are then detected with a computed tomography (CT) scan. In phase I patient trials, Tc-99m MIP-1404 was ready to be imaged by CT scan within 1 hour after injection into the body and pointed out more tumors than standard bone scans. Phase II clinical trials are ongoing.